Educational Workshops
One Day Science Symposium - Sevgi Aral, Centre for Disease Control and Prevention & James Blanchard, University of Manitoba
Date: Sunday 13 September 2015
Time: 8.30am - 5.00pm
Location: Room P1 Brisbane Convention & Exhibition Centre
Cost: Complimentary
Queensland Community PrEP Forum
On Tuesday evening from 6:00pm – 8:00pm, the HIV Foundation
Queensland is hosting a Community PrEP Forum being held at the Brisbane
Convention Centre.
This is a free event open to the public and Heath Paynter
from the Victorian AIDS Council will be facilitating the event.
PrEP in Australia and Queensland: Find out about
options for access and costs now and plans for the future – Dr Darren Russell
PrEP in San Francisco: Hear about the social and
cultural power of PrEP and how it has changed HIV in San Francisco from the man
who led the way – Prof. Bob Grant
What’s it like to be on PrEP: Your chance to hear
directly from someone about their experience of what it’s like.
Get your questions answered: The speakers will form a
panel with GP, Dr Fiona Bisshop for an interactive discussion to answer any
questions you may have on PrEP. View the Forum flyer
HIV prevention has changed.
Come to the forum to find out more.
Penelope Lowe Trainee Breakfast
Date: Wednesday 16 September 2015
Time: 7.00am - 8.45am
Location: Brisbane Convention & Exhibition Centre
Cost: $33.00
AFAO Community and Advocacy
Hub: call for community videos and posters
The Australian Federation of AIDS
Organisations (AFAO) will once again be hosting a Community and Advocacy Hub at
the 2015 Australasian HIV & AIDS Conference.
The Hub is a dynamic community space which
will highlight programs, services and key focus areas for organisations
involved in Australia’s community response to HIV.
The Hub will also feature a selection of
HIV/STI-related short films and health promotion resources from community
organisations working across Australia and the Asia-Pacific region.
AFAO is pleased to invite community
organisations and groups to submit short films and posters for display. Expression
of interest should be sent to Finn O’Keefe at AFAO by 31 August.
Email: fokeefe@afao.org.au.au or for further information see: http://bit.ly/1DQVIN3
Satellite Meetings
Gates Foundation Satellite
Date: Sunday 13 September 2015
Time: 1.30pm - 3.00pm
Location: Brisbane Convention & Exhibition Centre
Cost: Complimentary
World Health Organisation Satellite
Date: Sunday 13 September 2015
Time: 3.30pm - 5.00pm
Location: Brisbane Convention& Exhibition Centre
Cost: Complimentary
Roche Satellite
Date: Monday 14 September 2015
Time: 7.30am - 9.00am
Location: Brisbane Convention& Exhibition Centre
Cost: Complimentary
Hologic Satellite
Date: Tuesday 15 September 2015
Time: 7.30am - 9.00am
Location: Brisbane Convention & Exhibition Centre
Cost: Complimentary
ViiV Satellite
Date: Wednesday 16 September 2015
Time: 7.00am - 8.45am
Location: Brisbane Convention& Exhibition Centre
Cost: Complimentary
Gilead Satellite #Wheretonext
Date: Thursday 17 September 2015
Time: 6.15pm - 8.30pm
Location: Brisbane Convention & Exhibition Centre
Cost: Complimentary
As HIV
treatment options continue to change and evolve, it is time to challenge
existing thinking, apply scientific innovation and ensure the best patient
outcomes are achieved with the treatments we have available today. This
is the aim of the Gilead Symposium. The first presentation, by Professor
Andrew Carr, will focus on single tablet regimens and ask the question: is this
regimen for a lifetime? The second presentation, by Professor Darren
Russell, will focus on using existing treatments as prevention; how can we make
the playground safer? Finally, Rubern Meehan will highlight how innovative
thinking, and application of scientific investigation might deliver outcomes
beyond today’s expectations. #wheretonext?
External Associated Events
Control and Elimination within Australia to Hepatitis C from People living with HIV (CEASE)
Treatments for Hepatitis C with Direct Acting Antivirals: Training for HIV prescribers
Hepatitis C has long been recognised as a major contributor to co-morbidity in people living with HIV. The HIV-HCV coinfected population is at high risk of accelerated progression to end stage liver disease, liver cancer and associated death. The availability of low toxicity directly acting antiviral drugs (DAA) is likely to revolutionise the potential for treatment on both an individual and population level basis, and are likely to be equally successful in HIV positive and negative individuals. Prescription of these regimens need to move from the specialist liver clinic to community based prescribers if large scale access to treatment is to be achieved.
This one-day course is designed for current HIV prescribers in order to up-skill the primary care based workforce to broaden their clinical role in management of HIV/HCV co-infection into management of HCV mono-infection. Topics to be covered include: information about the CEASE project; emerging therapies; their timelines and implications for treatment decision making; DAAs for HIV/HCV co-infection; assessment of liver disease; and more.
Date: Saturday 19 September 2015
Time: 9.00am - 5.00pm
Venue: TBC Brisbane
